Log In
BCIQ
Print this Print this
 

OPS202, SOMscan

  Manage Alerts
Collapse Summary General Information
Company Ipsen Group
DescriptionGallium-68-labeled radioactive agent for PET imaging that antagonizes somatostatin receptor 2 (SSTR2)
Molecular Target Somatostatin receptor 2 (SSTR2)
Mechanism of ActionImaging agent
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I/II
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnostic agent for managing neuroendocrine tumors; Diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors
Regulatory Designation U.S. - Orphan Drug (Diagnostic agent for managing neuroendocrine tumors);
EU - Orphan Drug (Diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$56.6M

$34.0M

$22.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/30/2015

$56.6M

$34.0M

$22.6M

Get a free BioCentury trial today